

April 19, 2023



# Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USA

REDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a pre-conference workshop highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES USA annual meeting being held May 7-10, 2023, in San Diego, CA. The workshop will be held live and virtually on Sunday, May 7, 2023.

Ribonucleic acid (RNA) as a therapeutic modality has gained tremendous traction in recent years with the growing number of messenger RNA (mRNA) vaccines and small interfering RNA (siRNA) candidates advancing in clinical studies. However, large-scale production faces complex challenges in nucleic acids quality and quantity, as well as overall economics. At TIDES USA, Codexis will showcase how engineered enzymes can overcome these difficulties to enable scalable and sustainable manufacturing.

## *Presentation Details*

**Title:** Engineered Enzymes to Overcome Scalability and Sustainability Challenges of Nucleic Acid Therapeutics Manufacturing

**Date:** Sunday, May 7, 2023

**Time:** 12:30 pm – 1:30 pm PT

**Location:** Manchester Grand Hyatt, San Diego, CA

An archive of the presentation will be available to registered attendees within the TIDES USA platform. The presentation will also be available on Codexis' website, [www.codexis.com](http://www.codexis.com).

## **About Codexis**

Codexis is a leading enzyme engineering company leveraging our proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and – as biotherapeutic candidates – they have the potential to treat challenging diseases. Our unique enzymes drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, greater sensitivity in genomic and diagnostic applications and potentially more efficacious therapeutics. For more information, visit [www.codexis.com](http://www.codexis.com).

## **Forward-Looking Statements**

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding how engineered enzymes have the potential to enable

scalable and sustainable manufacturing of mRNA vaccines and siRNA product candidates. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis' control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 27, 2023, including under the caption "Risk Factors," and in Codexis' other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

### **For More Information**

Investor Contact  
Carrie McKim  
(336) 608-9706  
[ir@codexis.com](mailto:ir@codexis.com)

Media Contact  
Lauren Musto  
(781) 572-1147  
[media@codexis.com](mailto:media@codexis.com)

**CODEXIS®**

Source: Codexis, Inc.